Business

Know the Business

IMCV is not a company. It is a passive index ETF run by BlackRock that rents you a basket of ~290 mid-cap U.S. value stocks for 6 basis points a year, with no human picking what's inside. The product matters only on three axes: cost, fidelity to the index, and how much money it has gathered. On the first two it is best-in-class; on the third it is a distant fifth in its own category, sitting next to a sister fund (IWS) that is 15× larger and 17 bp more expensive. The most likely thing the market gets wrong is treating these mid-cap value ETFs as interchangeable — the underlying indices look similar but tilt very differently when cycles turn.

1. How This Business Actually Works

IMCV does not earn revenue — it pays it. The fund collects 0.06% a year from shareholders (about $380K of net advisory fees in FY2025 on $643M of average assets) and hands it to BlackRock Fund Advisors, which in turn absorbs almost every operating cost the fund would otherwise bear. The shareholder's "P&L" is the underlying portfolio's dividends minus that fee, plus mark-to-market changes in the holdings. There is no operating leverage, no moat, and no management discretion to add or destroy value.

The mechanics that decide whether shareholders get what they paid for:

Three things to internalize. First, scale economics are real but capped by competition: a 0.06% fee on $1B is $600K of revenue for BlackRock — trivial. The economics for BFA come from rolling up dozens of these series under one operating platform; IMCV alone could not exist as a standalone business. Second, the in-kind creation/redemption mechanism is the single most important feature of the product, because it externalizes turnover costs to APs and minimizes capital-gains distributions to shareholders (FY2025 distributions were 100% ordinary income, not realized gains). Third, the only real way IMCV "fails" the shareholder is tracking error — it has been near-zero (10Y NAV: 10.07% vs benchmark 10.23%, the 0.16 ppt gap is essentially the fee plus a small tax/dividend timing drag).

The fee dropped from 0.27% to 0.06% on March 22, 2021 when iShares re-platformed JKI as IMCV and switched the underlying index from Morningstar US Mid Value to the Broad Value variant. That is the entire economic history of the product worth knowing.

2. The Playing Field

There are six mid-cap value ETFs that any allocator will weigh against each other. They look similar; they are not. IMCV ties Vanguard's VOE for the cheapest fee, but VOE has gathered ~35× more assets and IWS — IMCV's own iShares sister fund tracking Russell Midcap Value — has 15× the assets at nearly 4× the fee.

What this peer set actually reveals:

The index choice matters more than the wrapper. The three S&P 400 Value funds (IJJ, MDYV, IVOV) hold the same 302 names at different fees and have produced visibly higher 10-year returns than Russell-based IWS — driven primarily by the S&P 400's GAAP-profitability screen, which kept unprofitable cyclicals out during the 2020–2022 stretch. CRSP-based VOE skews larger (its universe reaches up the cap ladder, holding more wide-moat names). Russell-based IWS is the broadest at 711 holdings but also the slowest because it has no quality filter and includes everything in the 201–1,000 cap range. IMCV's Morningstar index sits in the middle — broader than S&P 400 Value, narrower than Russell, and uses five valuation ratios rather than two.

The fee gap is sticky and unjustified by performance. IWS earns BlackRock 17 bp more than IMCV with materially worse 5-year returns. The reason it persists: IWS launched in 2001, accumulated assets over two decades of advisor habit, and switching costs (capital gains, model-portfolio changes) keep flows lazy. IMCV is what an iShares allocator should buy today; IWS is what was bought yesterday.

The AUM gap with VOE is the real competitive story. IMCV and VOE charge essentially the same fee. VOE has 35× more assets because it has 20 extra years of advisor relationships, deeper liquidity (0.02% spread vs 0.07%), and Vanguard's structural advantage in the model-portfolio channel. IMCV cannot close that gap; it can only compete on tax efficiency and incremental flow at the margin.

3. Is This Business Cyclical?

Yes — but the cycle that matters is the style cycle, not the business cycle. IMCV is a pass-through to a specific factor (mid-cap value), and its performance vs the broader market is determined entirely by whether value is in or out of favor and whether mid-caps are leading or lagging mega-caps.

The pattern is clean. IMCV outperforms when value works — that means recovering from bear markets (2021 +33%), bear markets themselves where it falls less (2022 -6.6% vs -18%), and rotations away from mega-cap growth (2026 YTD). It underperforms in mega-cap-growth regimes (2023–2025) by a wide margin. The factor history matters: over the last decade through mid-2023, the broad U.S. mid-cap index lagged large caps by ~3 ppts annualized; mid-cap value funds saw ~$106B of net outflows over five years.

There is also a sector-cycle layer underneath. IMCV's portfolio is 16% Financials, 13% Energy, 12% Industrials, 10% Utilities, 9% Consumer Staples — a defensive/cyclical/income blend. Rate-cut cycles help financials and utilities; reshoring helps industrials; oil drawdowns hurt energy. The healthcare detractor in FY2025 (biotech/life-sciences pressure) and the utilities tailwind (AI data-center power demand) are the kinds of intra-portfolio cycles that show up as ±2 ppt deviations from the index, not larger swings.

4. The Metrics That Actually Matter

Most ETF screens are filled with metrics that compound to noise. For a passive index ETF, only five numbers genuinely matter, and three of them — expense ratio, tracking gap, AUM — IMCV already wins on.

What this scorecard is saying:

Expense ratio is the only metric where small differences matter a lot. A 17 bp gap (IMCV vs IWS) compounded over 30 years is roughly a 5% portfolio shortfall. Nothing else in this scorecard moves the needle that much.

Tracking gap of 16 bp is the right answer. A passively run index ETF should miss its benchmark by approximately the fee plus a few basis points of dividend-timing and sampling drag. IMCV does. If you saw a 50+ bp gap, you'd be looking at a sampling problem or a hidden cost. You're not.

Bid-ask spread is what most retail buyers ignore and quietly pay. IMCV's 0.07% spread is wider than VOE (0.02%) or IWS (0.02%) because of lower volume (~32K shares/day vs VOE's millions). For a one-time long-term buy, this is a non-issue. For a tactical position rotated quarterly, it adds 25 bp/year of friction — more than four years of expense ratio.

The metrics most people focus on (1Y return, NAV, distribution yield) tell you almost nothing about the ETF — they tell you about the underlying market. Don't confuse the two.

5. What I'd Tell a Young Analyst

One. The ETF is not the investment thesis. The thesis is the factor (mid-cap U.S. value) and the index methodology (Morningstar Broad Value). Decide on those first; the ETF wrapper is the cheapest implementation.

Two. When two ETFs track the same factor, fee compresses; when they track different indices labeled the same way, fee gaps mean nothing. IWS at 0.23% and IMCV at 0.06% are not the same product — Russell Midcap Value (711 holdings, no profitability screen) and Morningstar Mid Cap Broad Value (~290 holdings, broader value definition) tilt differently in cycles. Compare indices, not just labels.

Three. The metric that would change my view: persistent capital-gains distributions. ETFs are tax-efficient because in-kind creation/redemption flushes appreciated lots. If IMCV ever distributed long-term capital gains in size (it has not), the wrapper itself would be impaired. Watch the year-end distribution announcements every November.

Four. What the market is most likely getting wrong here: assuming mid-cap value and large-cap value are interchangeable. They are not. Over the last 10 years mid-caps lagged large-caps by ~3 ppts annualized — and the gap was driven almost entirely by mega-cap concentration. If that concentration unwinds (as it began to in early 2026), IMCV's relative performance flips. That is the only reason to own this fund tactically; if you don't believe in factor mean-reversion, hold large-cap value instead.

Five. What would change the thesis: a permanent regime where mega-cap growth stays >50% of market cap. In that world, the mid-cap value factor stops mean-reverting, and indexing into it via IMCV becomes a slow-burn underperformance. Watch the Russell 1000 Growth / Russell 1000 Value ratio and the top-10 S&P 500 concentration — those are the two charts that decide whether this fund earns its premium.